Erenumab in the prophylaxis of migraine: a profile of its use
- 48 Downloads
Erenumab (Aimovig®, erenumab-aooe), a fully human monoclonal antibody (MAb) calcitonin gene-related peptide (CGRP) receptor antagonist, is the first MAb approved for the prophylaxis of migraine in adults. Erenumab is subcutaneously administered and has a convenient once-monthly/every-4-week dosing regimen. In patients with episodic or chronic migraine, erenumab is effective and generally well tolerated, significantly reducing the frequency of migraines and the use of migraine-specific medications during weeks 9–12 and months 4–6 relative to placebo. Erenumab also displays efficacy in numerous subgroup analyses, including in patients with episodic or chronic migraine with prior prophylactic treatment failure and/or patients with a history of aura. Although the efficacy and tolerability profiles of erenumab remain to be determined in specific populations (for example, in patients with major cardiovascular disease), it is a promising candidate for alleviating the widespread personal, societal and economic burdens that are presently associated with migraine.
The manuscript was reviewed by: H.-C. Diener, Faculty of Medicine, University Duisburg-Essen, Essen, Germany; J. de Hoon, Center for Clinical Pharmacology, University Hospitals of Leuven, Leuven, Belgium. During the peer review process, Amgen Inc. and Novartis Pharmaceutical Corporation, the marketing-authorization holders of erenumab (Aimovig®), were also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
E.H. McCafferty and K.A. Lyseng-Williamson are employees of Adis, are responsible for the article content and declare no conflicts of interest.
- 2.NICE (National Institute for Health and Care Excellence). Headaches in over 12s: diagnosis and management (CG150). London: NICE; 2012.Google Scholar
- 3.World Health Organization. Fact sheet: headache disorders. Geneva: World Health Organization; 2016.Google Scholar
- 7.Steiner T, MacGregor E, Davies P. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication overuse headache, 3rd edition (1st revision). Hull: British Association for the Study of Headache; 2010.Google Scholar
- 9.Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22–33.Google Scholar
- 14.Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.CrossRefGoogle Scholar
- 23.Aimovig (erenumab): EU summary of product characteristics. Dublin: Novartis Europharm Limited; 2018. https://www.ema.europa.eu/documents/product-information/aimovig-epar-product-information_en.pdf. Accessed 11 Oct 2018.
- 24.Aimovig™ (erenumab-aoee) injection, for subcutaneous use: US prescribing information. Thousand Oaks: Amgen Inc.; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf. Accessed 11 Oct 2018.
- 26.Xu Y, Gabriel K, Wang Y, et al. A multicenter, open-label, pharmacokinetic drug interaction study of erenumab (AMG 334) and a combined oral contraceptive in healthy female subjects [abstract no. PS23]. Headache. 2017;57(Suppl 3):192–3.Google Scholar
- 27.de Hoon J, Van Hecken A, Vandermeulen C, et al. Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. Cephalalgia. 2018. https://doi.org/10.1177/0333102418776017.Google Scholar
- 33.Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018. https://doi.org/10.1016/s0140-6736(18)32534-0.Google Scholar
- 38.Paemeleire K, Broessner G, Brandes J, et al. Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s) [abstract no. O1]. J Headache Pain. 2017;18(Suppl 1):135–6.Google Scholar
- 39.Pascual J, Buse DC, Starling AJ, et al. Effect of erenumab on patient-reported outcomes in episodic migraine patients with prior prophylactic treatment failure: results from a post-hoc analysis of the STRIVE study [abstract no. PS49]. Headache. 2018;58(Suppl 2):179–80.Google Scholar
- 40.McAllister P, Gomez JP, McGill L, et al. Efficacy of erenumab for the treatment of patients with episodic migraine with aura [abstract no. P4.094]. Neurology. 2018;90(15 Suppl).Google Scholar
- 41.Tepper S, Broessner G, Buse D, et al. Efficacy of erenumab for the treatment of patients with episodic migraine with depression and/or anxiety [abstract no. P4.105]. Neurology. 2018;90(15 Suppl).Google Scholar
- 42.Pavlovic J, Paemeleire K, Gobel H, et al. Efficacy of erenumab in women with and without a history of menstrually-related migraine [abstract no. P4.096]. Neurology. 2018;90(15 Suppl).Google Scholar
- 44.Lanteri-Minet M, Buse DC, Starling AJ, et al. Patient-reported outcomes in chronic migraine patients with prior prophylactic treatment failure receiving placebo or erenumab: subgroup analysis of a pivotal randomized study [abstract no. PS36]. Headache. 2018;58(Suppl 2):170–1.Google Scholar
- 45.Diener HC, Ashina M, Brandes J, et al. Efficacy of erenumab for the treatment of patients with chronic migraine in presence of medication overuse [abstract no. PR1048]. Eur J Neurol. 2017;(Suppl 1):472.Google Scholar
- 46.Ashina M, Dodick D, Goadsby P, et al. Efficacy of erenumab for the treatment of patients with chronic migraine with and without aura [abstract no. S32.006]. Neurology. 2018;90(15 Suppl).Google Scholar
- 47.Assessment report: Aimovig. London: European Medicines Agency; 2018.Google Scholar
- 48.Winner P, Reuter U, Dodick D, et al. Erenumab safety among migraine patients using triptans or with cardiovascular (CV) risk factors [abstract no. P4.100]. Neurology. 2018;90(15 Suppl).Google Scholar
- 49.Tepper S, Pascual J, Reuter U, et al. Analysis of blood pressure following short-term and long-term treatment with erenumab [abstract no. P4.103]. Neurology. 2018;90(15 Suppl).Google Scholar
- 50.Vargas B, Starling A, Silberstein S, et al. Erenumab immunogenicity: a pooled analysis of phase 2 and phase 3 migraine prevention clinical trials [abstract no. P4.098]. Neurology. 2018;90(15 Suppl).Google Scholar